BYAHConsumer Defensive · Household & Personal Products

BYAH Stock Forecast: Park Ha Biological Technology Co. Ltd. Price Predictions for 2026-2027

Last close, 2 Oct 2026

$2.35

+3.52% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 2 Oct 2026 — in the lower half.

Market cap

$1.8M

Ticker Nerd rank

25 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−15.2%

−13.0%

YTD

−96.3%

−98.8%

From 52W high

−98.8%

From 52W low

+3.5%

$195

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

BYAH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Park Ha Biological Technology Co. Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 2 Oct 2026

25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Accruals

Growth

Value

Revisions

Momentum

Quality

Issuance

Volatility

Size (95): Smaller than most of the companies we track.

Volatility (7): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

BYAH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on BYAH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BYAH appears on the weeks it earns a place.

Performance

BYAH vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 2 Oct 2026, Park Ha Biological Technology Co. Ltd. returned −98.8% against +16.2% for the S&P 500, dividends included.

BYAH vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

BYAH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Park Ha Biological Technology Co. Ltd. (BYAH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: 0.7×
Price / book: 0.3×
EV / EBITDA: 0.8×

Growth & margins

Revenue growth (YoY): 1.5%
Earnings growth (YoY): —
Gross margin: —
Operating margin: −76.5%
Net margin: −214.2%

Returns & dividend

Return on equity: −113.0%
Return on assets: −50.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Park Ha Biological Technology Co. Ltd. (BYAH) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Park Ha Biological Technology Co. Ltd. has a market value of $1.8M and an enterprise value of −$4.1M.
Shares outstanding: 677,488.
Park Ha Biological Technology Co. Ltd. employs 41 people.

market figures as at 2 Oct 2026

Data provided by Twelve Data

Peers

BYAH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHousehold & Personal Products

Company	Market cap	TKN rank
BYAHPark Ha Biological Technology Co. Ltd.	$1.8M	25
TANHTantech Holdings Ltd.	$9.9M	16
ATTTAtlas Trinity Tech Ltd.	$15.8M	11
BIOTInstinct Bio Technical Co. Holdings, Inc.	$1.5M	18
DSYBig Tree Cloud Holdings Ltd.	$29.4M	5
UGUnited-Guardian, Inc.	$32.8M	91
GROVGrove Collaborative Holdings, Inc.	$43.7M	92

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Park Ha Biological Technology Co. Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest BYAH news & analysis

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH

GlobeNewsWire · 28 Sept 2026negative

Levi & Korsinsky has reminded BYAH shareholders of a lead plaintiff deadline of September 28, 2026 in a lawsuit against Park Ha Biological Technology Co., Ltd. The lawsuit alleges BYAH structured its IPO with a public float of under 5% of the company, a structure it contends enabled coordinated price manipulation before BYAH shares fell 93% in a single session.

Why it matters — BYAH watchers may want to note the active securities lawsuit and its September 2026 lead plaintiff deadline, which centres on allegations tied to the company's IPO structure and a sharp share-price decline.

PHH, BYAH Deadline: PHH, BYAH Investors with Losses in Excess of $100K Have Opportunity to Lead Park Ha Biological Technology Co., Ltd. Securities Lawsuit

PRNewsWire · 21 Sept 2026negative

Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Park Ha Biological Technology Co., Ltd. securities that they have an opportunity to lead a securities lawsuit. The notice targets BYAH investors with losses in excess of $100,000 ahead of a deadline.

Why it matters — A securities class-action lawsuit reminder signals potential legal and financial exposure for BYAH that shareholders following the company would want to track.

FAQ

Frequently asked questions about BYAH stock

How does Ticker Nerd's model rank BYAH?

As at 2 Oct 2026, Park Ha Biological Technology Co. Ltd. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the BYAH stock forecast for 2030?

No analyst covering Park Ha Biological Technology Co. Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BYAH are extrapolating price history, which says nothing about the business.

How has BYAH stock performed over the past year?

Park Ha Biological Technology Co. Ltd. returned -98.8% over the 12 months to 2 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Park Ha Biological Technology Co. Ltd. do?

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products.

What is the latest news on BYAH?

The most recent item we track (GlobeNewsWire, 28 Sept 2026): "Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Park Ha Biological Technology Co., Ltd. Lawsuit - BYAH". Levi & Korsinsky has reminded BYAH shareholders of a lead plaintiff deadline of September 28, 2026 in a lawsuit against Park Ha Biological Technology Co., Ltd. The lawsuit alleges BYAH structured its IPO with a public float of under 5% of the company, a structure it contends enabled coordinated price manipulation before BYAH shares fell 93% in a single session.

Company

About Park Ha Biological Technology Co. Ltd.

Park Ha Biological Technology Co., Ltd. Class A Ordinary Shares represents equity in Park Ha Biological Technology Co., Ltd., a Wuxi-based company focused on skincare and cosmetic products. The company develops and sells private-label skincare offerings under the Park Ha brand, serving consumers in China through direct product sales and franchise-related channels. Its business also includes franchise services and complementary after-sales beauty services provided through directly operated and franchised locations. Park Ha Biological Technology operates as a holding company with a consumer-focused model centered on personal care and beauty products. The Class A Ordinary Shares provide exposure to a business positioned within the household and personal care segment of the broader consumer market.

CEO Ms. Xiaoqiu Zhang · 41 employees · China · https://parkha.cn